Mariam Chalabyan, Research Project Manager at BostonGene, shared a post on LinkedIn:
“I am incredibly grateful to have contributed as a co-author on an e-poster presented at the ESMO 2026 congress. This research was a collaboration between BostonGene and MD Anderson Cancer Center IBC team, focusing on an integrated multiomic analysis of triple-negative inflammatory breast cancer patients by response to KEYNOTE-522 regimen.
For me, its a privilege to play a small part in advancing understanding in oncology alongside such a talented group of professionals.
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 5
